These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37184290)

  • 1. Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials.
    Simpson EL; Rahawi K; Hu X; Chu AD; Nduaka C; Jazayeri S; Lio P; Lynde C; Schuttelaar MLA
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1863-1870. PubMed ID: 37184290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
    Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
    Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials.
    Paller AS; Ladizinski B; Mendes-Bastos P; Siegfried E; Soong W; Prajapati VH; Lio P; Thyssen JP; Simpson EL; Platt AM; Raymundo EM; Liu J; Calimlim BM; Huang X; Gu Y; Hu X; Yang Y; Su JC; Zheng M; Yamamoto-Hanada K; Teixeira HD; Irvine AD
    JAMA Dermatol; 2023 May; 159(5):526-535. PubMed ID: 37043227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials.
    Simpson EL; Papp KA; Blauvelt A; Chu CY; Hong HC; Katoh N; Calimlim BM; Thyssen JP; Chiou AS; Bissonnette R; Stein Gold LF; Wegzyn C; Hu X; Liu M; Liu J; Tenorio AR; Chu AD; Guttman-Yassky E
    JAMA Dermatol; 2022 Apr; 158(4):404-413. PubMed ID: 35262646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.
    Kamphuis E; Loman L; Han HL; Romeijn GLE; Politiek K; Schuttelaar MLA
    Contact Dermatitis; 2023 May; 88(5):351-362. PubMed ID: 36621910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
    Simpson EL; Prajapati VH; Leshem YA; Chovatiya R; de Bruin-Weller MS; Ständer S; Pink AE; Calimlim BM; Lee WJ; Teixeira H; Ladizinski B; Hu X; Yang Y; Liu Y; Liu M; Grada A; Platt AM; Silverberg JI
    Dermatol Ther (Heidelb); 2024 May; 14(5):1127-1144. PubMed ID: 38696027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics.
    Thyssen JP; Thaçi D; Bieber T; Gooderham M; de Bruin-Weller M; Soong W; Kabashima K; Barbarot S; Luna PC; Xu J; Hu X; Liu Y; Raymundo EM; Calimlim BM; Nduaka C; Gamelli A; Simpson EL
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1871-1880. PubMed ID: 37247226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
    Silverberg JI; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Costanzo A; Rosmarin D; Lynde C; Liu J; Gamelli A; Zeng J; Ladizinski B; Chu AD; Reich K
    J Allergy Clin Immunol; 2022 Mar; 149(3):977-987.e14. PubMed ID: 34403658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis.
    Silverberg JI; Adam DN; Zirwas M; Kalia S; Gutermuth J; Pinter A; Pink AE; Chiricozzi A; Barbarot S; Mark T; Tindberg AM; Weidinger S
    Am J Clin Dermatol; 2022 Jul; 23(4):547-559. PubMed ID: 35857179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.
    Oosterhaven JAF; Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
    J Dermatol; 2019 Aug; 46(8):680-685. PubMed ID: 31187925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study.
    Voorberg AN; Kamphuis E; Christoffers WA; Schuttelaar MLA
    Br J Dermatol; 2023 Sep; 189(4):400-409. PubMed ID: 37170922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry.
    Voorberg AN; Romeijn GLE; de Bruin-Weller MS; Schuttelaar MLA
    Contact Dermatitis; 2022 Aug; 87(2):185-191. PubMed ID: 35279856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
    Guttman-Yassky E; Silverberg JI; Thaçi D; Papp KA; Ständer S; Beck LA; Kim BS; Hu X; Liu J; Calimlim BM; Vigna N; Crowley JT; Teixeira HD; Thyssen JP
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2558-2568. PubMed ID: 37528500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
    Guttman-Yassky E; Thaçi D; Pangan AL; Hong HC; Papp KA; Reich K; Beck LA; Mohamed MF; Othman AA; Anderson JK; Gu Y; Teixeira HD; Silverberg JI
    J Allergy Clin Immunol; 2020 Mar; 145(3):877-884. PubMed ID: 31786154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.
    Magnolo N; Cameron MC; Shahriari M; Geng B; Calimlim BM; Teixeira H; Hu X; Yang Y; Liu Y; Zhang S; Sancho Sanchez C; Altman K; Langley RG
    J Dermatolog Treat; 2024 Dec; 35(1):2344589. PubMed ID: 38697950
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysis.
    Katoh N; Ohya Y; Murota H; Ikeda M; Hu X; Ikeda K; Liu J; Sasaki T; Chu AD; Teixeira HD; Saeki H
    JAAD Int; 2022 Mar; 6():27-36. PubMed ID: 34988493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.